Key result
Review highlights genetic testing to optimize antiplatelet safety and efficacy for stroke prevention.
Why the study?
Platelet activation and aggregation play a major role in ischemic stroke, and certain patient subtypes may benefit more than others from specific antiplatelet regimens across primary, secondary, and tertiary prevention.
This review summarizes the pharmacological evidence for antiplatelet therapies in ischemic stroke prevention, highlighting the potential for precision medicine and genetic testing to optimize safety and efficacy.
Answers are grounded in this paper and cite their sources.
Genetic testing may guide antiplatelet selection in stroke prevention; leaves open need for prospective validation before clinical adoption.
INTRODUCTION: Ischemic etiology accounts for two thirds of all strokes in which platelet activation and aggregation play a major role. A variety of antiplatelet therapies have been tested for primary, secondary, and tertiary prevention, with certain patient subtypes benefiting more than others from a specific regimen. AREAS COVERED: This review aims at synthetizing current evidence on pharmacology of antiplatelet agents approved for primary, secondary, and tertiary stroke prevention and their application among possible patient subtypes that may benefit more from their administration. EXPERT OPINION: and phosphodiesterase inhibitors, also used in combination, as well as precision medicine approaches using genetic testing aiming at optimizing the safety and efficacy in this population.
No takes yet. Share an insight, caveat, or question.
Laudani et al. (2024) conducted a review in Ischemic stroke. Antiplatelet agents was evaluated. This review synthesizes current evidence on the pharmacology of antiplatelet agents for stroke prevention, highlighting precision medicine approaches using genetic testing to optimize safety and efficacy.
Synapse has enriched 10 related papers. Consider them for comparative context: